Alpha Tau Medical shares surge 71.87% after-hours after first patient treated in glioblastoma pilot study.

Alpha Tau Medical surged 71.87% in after-hours trading following the announcement that the first patient with recurrent glioblastoma was treated using its Alpha DaRT® technology in a pilot study. The milestone, achieved at The Ohio State University, marks a critical step in advancing the treatment for a highly aggressive brain cancer with limited therapeutic options. The company highlighted the technology’s potential to deliver precise alpha-radiation therapy while minimizing damage to healthy tissue, supported by regulatory designations such as the FDA’s Breakthrough Device Designation. The pilot study aims to evaluate feasibility and safety, with initial results demonstrating over 95% tumor volume coverage. Investors likely interpreted the event as a validation of Alpha Tau’s innovative approach and a catalyst for accelerated regulatory and commercial progress, driving the sharp post-market increase.